RHCG and TCAF 1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy

Purpose: The lack of biomarkers that can distinguish aggressive from indolent prostate cancer has caused substantial overtreatment of clinically insignificant disease. Here, by genome-wide DNA methylome profiling, we sought to identify new biomarkers to improve the accuracy of prostate cancer diagnosis and prognosis. Experimental design: Eight novel candidate markers, COL4A6, CYBA, TCAF1 (FAM115A), HLF, LINC01341 (LOC149134), LRRC4, PROM1, and RHCG, were selected from Illumina Infinium HumanMethylation450 BeadChip analysis of 21 tumor (T) and 21 non-malignant (NM) prostate specimens. Diagnostic potential was further investigated by methylation-specific qPCR analysis of 80 NM vs. 228 T tissue samples. Prognostic potential was assessed by Kaplan-Meier, uniand multivariate Cox regression analysis in 203 Danish radical prostatectomy (RP) patients (cohort 1), and validated in an independent cohort of 286 RP patients from Switzerland and the U.S. (cohort 2). Results: Hypermethylation of the 8 candidates was highly cancer-specific (area under the curves: 0.79-1.00). Furthermore, high methylation of the 2-gene panel RHCG-TCAF1 was predictive of biochemical recurrence (BCR) in cohort 1, independent of the established clinicopathological parameters Gleason score, pathological tumor stage, and pre-operative PSA (HR (95% confidence interval (CI)): 2.09 (1.26 3.46); P = 0.004), and this was successfully validated in cohort 2 (HR (95% CI): 1.81 (1.05 3.12); P = 0.032). Conclusion: Methylation of the RHCG-TCAF1 panel adds significant independent prognostic value to established prognostic parameters for prostate cancer and thus may help to guide treatment decisions in the future. Further investigation in large independent cohorts is necessary before translation into clinical utility.

[1]  K. D. Sørensen,et al.  Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling , 2016, Oncotarget.

[2]  Hongyan Wu,et al.  TRPM8: a potential target for cancer treatment , 2016, Journal of Cancer Research and Clinical Oncology.

[3]  Riten Mitra,et al.  Zodiac: A Comprehensive Depiction of Genetic Interactions in Cancer by Integrating TCGA Data. , 2015, Journal of the National Cancer Institute.

[4]  Anamaria Crisan,et al.  Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. , 2015, European urology.

[5]  Y. De Launoit,et al.  TRP channel–associated factors are a novel protein family that regulates TRPM8 trafficking and activity , 2015, The Journal of cell biology.

[6]  Minghua Wu,et al.  Function and mechanism of tumor suppressor gene LRRC4/NGL-2 , 2014, Molecular Cancer.

[7]  S. Asuthkar,et al.  The TRPM8 Protein Is a Testosterone Receptor , 2014, The Journal of Biological Chemistry.

[8]  K. D. Sørensen,et al.  Prognostic DNA Methylation Markers for Prostate Cancer , 2014, International journal of molecular sciences.

[9]  P. Febbo,et al.  A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.

[10]  M. Mikuła,et al.  DNA methylation status is more reliable than gene expression at detecting cancer in prostate biopsy , 2014, British Journal of Cancer.

[11]  Peng Qiu,et al.  TCGA-Assembler: open-source software for retrieving and processing TCGA data , 2014, Nature Methods.

[12]  K. D. Sørensen,et al.  Hypermethylation of the GABRE∼miR-452∼miR-224 Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy , 2014, Clinical Cancer Research.

[13]  K. Chiam,et al.  Epigenetic biomarkers in prostate cancer: Current and future uses. , 2014, Cancer letters.

[14]  Robert Lowe,et al.  Marmal-aid – a database for Infinium HumanMethylation450 , 2013, BMC Bioinformatics.

[15]  K. D. Sørensen,et al.  DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  William L. Welbourn,et al.  Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. , 2013, International journal of radiation oncology, biology, physics.

[17]  B. Trock,et al.  Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high‐risk cohort of men with negative initial prostate biopsies , 2012, BJU international.

[18]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[19]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[20]  W. Huttner,et al.  Prominin‐1 (CD133) is not restricted to stem cells located in the basal compartment of murine and human prostate , 2011, The Prostate.

[21]  Mickael Guedj,et al.  Should We Abandon the t-Test in the Analysis of Gene Expression Microarray Data: A Comparison of Variance Modeling Strategies , 2010, PloS one.

[22]  Allen D. Delaney,et al.  Conserved Role of Intragenic DNA Methylation in Regulating Alternative Promoters , 2010, Nature.

[23]  S. Freedland,et al.  Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. , 2010, The Journal of urology.

[24]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[25]  G. Kristiansen,et al.  DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy. , 2009, The Journal of urology.

[26]  P. Houillier,et al.  A role for Rhesus factor Rhcg in renal ammonium excretion and male fertility , 2008, Nature.

[27]  Li Wang,et al.  Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas , 2008, BMC Molecular Biology.

[28]  J. Herman,et al.  Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. , 2008, Cancer research.

[29]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[30]  Jack A. M. Leunissen,et al.  Turning CFCs into salt. , 1996, Nucleic Acids Res..

[31]  B. Croker,et al.  Expression of the ammonia transporter, rh C glycoprotein, in normal and neoplastic human kidney. , 2006, Journal of the American Society of Nephrology : JASN.

[32]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[33]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[34]  A. Harris,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.

[35]  G. Rubin,et al.  Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Ming-Rong Wang,et al.  RhCG is downregulated in oesophageal squamous cell carcinomas, but expressed in multiple squamous epithelia. , 2002, European journal of cancer.

[37]  T. Esen,et al.  Discrepancy between Gleason Scores of Biopsy and Radical Prostatectomy Specimens , 2000, European Urology.

[38]  J. Foidart,et al.  Loss of type IV collagen alpha 5 and alpha 6 chains in human invasive prostate carcinomas. , 1997, The American journal of pathology.

[39]  Y. Hochberg.  A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[40]  F. Harrell,et al.  Evaluating the yield of medical tests. , 1982, JAMA.